Reported Revenue - Truenewj

Guggenheim reaffirmed its purchase of GeneDx in late October and raised the price target to 0 after outperforming the third quarter

Guggenheim reaffirmed its purchase of GeneDx in late October and raised the price target to $170 after outperforming the third quarter

amefika7 months ago02 mins

GeneDx Holdings Corp. (NASDAQ:WGS) is one of the The best digital health stocks to buy now. On October 29, 2025, Guggenheim raised GeneDx (NASDAQ:WGS) to a price target of $170 (Buy) following the company’s dramatic third-quarter announcement a day earlier. GeneDx had just reported revenue of $116.7 million, up 52% year-over-year and roughly ~12% ahead…

Q2 Productivity Software Stocks Roundup: monday.com (NASDAQ:MNDY) vs. Peers

amefika7 months ago05 mins

Let’s delve into the relative performance of monday.com (NASDAQ:MNDY) and its peers as we analyze the now-concluded second-quarter productivity software earnings season. Rising employee costs and the shift toward more remote work have increased the ever-present pressure to improve corporate productivity, which in turn has driven growing demand for productivity software that enables remote work,…